Loading stock data…
TCMD
$22.89-0.13 (-0.56%)
Market ClosedLast close May 1
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tactile Systems Technology, Inc. in the Healthcare sector is trading at $22.89. The stock is currently 39% below its 52-week high of $37.77, remaining 5.0% above its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why TCMD maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.89
Potential Downside
36.3%
Whystock Fair Value$14.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of ly...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$567.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
30.44
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.90%
Volume
Today's trading volume
308,079
Recent News
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +19.66% and +1.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Story Is Shifting For Tactile Systems Technology (TCMD) After Q4 And 2026 Guidance
The fair value estimate for Tactile Systems Technology is set at US$38.00, matching the prior US$38 target and indicating a consistent view of upside potential. This stable fair value is based on Street research that shows a wide range of opinions, from more optimistic views in the high US$30s and low US$40s to more cautious perspectives in the low US$30s following strong Q4 results and updated long term estimates. Below, you will see how this evolving narrative and the latest guidance may...
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.
Wall Street Analysts See a 41.11% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.